Uveitis

There were no significant differences between dexamethasone and fluocinolone acetonide intravitreal implants in controlling inflammation; however, the latter is considered more difficult to use.

A submitted column on how to properly care for patients suffering from vision loss from the founder and medical director of Focus Clinics in London.

A decade of fine-tuning proven therapies and embracing advancing clinical technology has put ophthalmology in a rare space.

Katherine Talcott, MD, of Cole Eye Institute, discusses results of a 5-year study examining endogenous bacterial endophthalmitis at a tertiary care center from AAO 2019.

Aleksandra Rachitskaya, MD, of Cole Eye Institute, discusses a presentation she led at AAO 2019 on novel imaging and surgical techniques.

Louis Pasquale, MD, professor of medicine at Icahn School of Medicine at Mount Sinai, discusses how technology and artificial intelligence has been embraced by ophthalmology.

Analysis of the FAST trial found that methotrexate performed better head-to-head than mycophenolate mofetil as a corticosteroid-sparing therapy.

Investigators presented 36-month results of a study which found that treatment with a single intravitreal injection of the FAi provided anti-inflammatory treatment for 3 years in patients with non-infectious uveitis affecting the posterior segment of the eye

Ajay Kuriyan, MD, discusses what he warns patients to be aware of when seeking out treatment from stem cell therapies and why he believes other physicians should as well.

Using a national medical claims database, investigators found the incidence and prevalence of uveitis in the US.

A new phase 3 study suggests that physicians should shift away from periocular injections, and towards intravitreal injections of corticosteroids for uveitic macular edema.

Yutiq, a fluocinolone acetonide intravitreal implant, is indicated for the treatment of chronic non-infectious uveitis that affects the posterior segment of the eye.

Use of a 0.18 mg fluocinolone acetonide intravitreal insert effectively lowered the rate of uveitis recurrences and cumulative total recurrent episodes.

The diagnostics of the disease is not only important for the initial evaluation, but also etiology and long-term management.

Nguyen has had the fortune of having been involved in the trials of all three.

Acute intraocular inflammation was less common for ranibizumab than aflibercept.

Review explores reducing corticosteroid use with immunomodulatory therapies.

People with noninfectious uveitis tend to have low vitamin D levels.

Report underscores the need to act quickly, refer patients with eye problems.

T. gondii is one of the most common causes of infectious posterior uveitis.

A Spanish research team found an association between testing positive for antibodies to adalimumab (Humira) and a worse outcome of uveitis, but only in those who tested positive permanently. They also found that this association correlated with undetectable trough levels of Humira.

Patients with intermediate uveitis (IU) have a high likelihood of achieving good long-term visual outcomes, but should expect a long disease course and frequent complications

Adalimumab (ADA) works well as a treatment for patients with both active and inactive uveitis whether or not they are taking an immunosuppressant (IMM); however, the median time to treatment failure (mTTF) is longer for patients with inactive uveitis taking an IMM.

Medical technology is constantly evolving across fields, and ophthalmology is no exception. A new hypersonic vitrectomy device is currently in development and could be on the market in 2017.

Before antibiotics, people went blind from syphilis. They still could, the US Centers for Disease Control and Prevention warned today.